-Delve Bio to Present Two Oral Presentations at American Academy of Neurology 2026 Annual Meeting- Delve Bio, a UCSF spin-out and pioneer in metagenomic next-generation sequencing (mNGS) for ...
BD-pTau 217 is a refined biomarker which enhances Alzheimer’s specificity while retaining the strengths of plasma pTau 217.
New peer-reviewed study from UT Southwestern Medical Center shows Summit found clinically significant variants in more than half of cytology-negative cases CHICAGO, May. 6, 2026 /PRNewswire/ -- A new ...
CHICAGO, April 25, 2025 /PRNewswire/ -- Belay Diagnostics, a CLIA/CAP accredited laboratory focused on the development and commercialization of molecular diagnostics targeting central nervous system ...
REDMOND, WA, UNITED STATES, January 15, 2026 /EINPresswire.com/ — The End Brain Cancer Initiative Partners with Belay Diagnostics to Raise Awareness of Diagnostic ...
(MENAFN- Investor Brand Network) Primary and metastatic central nervous system (CNS) tumors can have extraordinary biological and anatomical complexity, and these tumors can be hard to identify using ...
BOSTON, April 16, 2026--(BUSINESS WIRE)--Delve Bio, a UCSF spin-out and pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, announced data underscoring the clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results